This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Prothena's (PRTA) Update on Pipeline Progress Disappoints
by Zacks Equity Research
Prothena (PRTA) provides updates on PRX012, PRX123, birtamimab and other programs. The delay in phase III data on birtamimab disappoints investors.
Biogen Inc. (BIIB) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $255.84, marking a -0.83% move from the previous day.
Biogen Inc. (BIIB) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $263.43, marking a -1.6% move from the previous day.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Biogen Inc. (BIIB) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
The latest trading day saw Biogen Inc. (BIIB) settling at $260.58, representing a -0.52% change from its previous close.
Ionis (IONS), AstraZeneca's Eplontersen Receives FDA Nod
by Zacks Equity Research
FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
by Zacks Equity Research
Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
Biogen's (BIIB) Rare Disease Drug Skyclarys Gets CHMP Nod in EU
by Zacks Equity Research
Biogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU for the treatment of Friedreich's ataxia in patients aged 16 years and older.
The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity
by Zacks Equity Research
Biogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog.
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
by Ekta Bagri
The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.
Why Is Biogen Inc. (BIIB) Up 6.4% Since Last Earnings Report?
by Zacks Equity Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
by Zacks Equity Research
Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market
by Zacks Equity Research
Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.
Ionis (IONS) Early-Stage Genetic Disorder Data Shows Promise
by Zacks Equity Research
Preliminary data from a phase I/IIa study on Ionis' (IONS) pipeline candidate, ION582, shows encouraging EEG and clinical observations in a phase I/IIa study.
Stock Market News for Nov 9, 2023
by Zacks Equity Research
U.S. stock closed mostly higher on Wednesday, with the S&P 500 and Nasdaq extending their longest winning streak in more than two years as investors weighed comments from Federal Reserve officials on future interest rates path.
Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5%
by Zacks Equity Research
Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
Pre-Markets Keep Streak Alive; RL, BIIB Beat
by Mark Vickery
The Dow rides its longest winning streak since July of this year, while the S&P and Nasdaq are enjoying their strongest moves since 2021.
Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View
by Zacks Equity Research
Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact of dilution from the Reata acquisition. Stock rises in pre-market.
Compared to Estimates, Biogen Inc. (BIIB) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Biogen Inc. (BIIB) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Why Biogen (BIIB) Might Surprise This Earnings Season
by Zacks Equity Research
Biogen (BIIB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Countdown to Biogen Inc. (BIIB) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Biogen Inc. (BIIB) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Another Big Batch of EPS Reports: Global Week Ahead
by John Blank
The U.S. earnings recovery that investors had been hoping for after a lukewarm first half of the year is so far coming to pass, but a number of major tests are still to come.
Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.